Richard R. DeLuca Jr. - 30 Apr 2024 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role
EVP&Pres, Merck Animal Heallth
Signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for Richard R. DeLuca, Jr.
Issuer symbol
MRK
Transactions as of
30 Apr 2024
Net transactions value
$0
Form type
4
Filing time
02 May 2024, 16:05:55 UTC
Previous filing
24 Jan 2024
Next filing
06 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MRK Common Stock 136,594 30 Apr 2024 Direct F1
holding MRK Common Stock - 401(k) Plan 1,237 30 Apr 2024 By 401(k) F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Restricted Stock Unit Award $0 +23,216 $0.000000 23,216 30 Apr 2024 Common Stock 23,216 Direct F3, F4
transaction MRK Stock Option (Right to Buy) Award $0 +37,500 $0.000000 37,500 30 Apr 2024 Common Stock 37,500 $129.22 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings include shares acquired in dividend reinvestment transactions.
F2 Includes shares acquired and dividends earned through April 5, 2024 in the Merck U.S. Savings Plan, a 401(k) plan.
F3 Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F4 These restricted stock units vest in full and are distributed as shares of Merck & Co., Inc. common stock on 04/30/2027.
F5 The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027.